News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wellington Management entities have disclosed a passive beneficial ownership stake of approximately 5.9% (3,229,882 shares) in Dianthus Therapeutics (DNTH) through a Schedule 13G filing. The shares are held by clients of various Wellington investment advisers, with Wellington reporting shared voting and dispositive power but …
Simon Read, a director at Dianthus Therapeutics Inc. (NASDAQ:DNTH), sold approximately $304,231 worth of common stock on August 10, 2026. This transaction involved the exercise of stock options and subsequent sale of 2,777 shares, executed under a Rule 10b5-1 trading plan. Following these sales, …
Adam M. Veness, SVP of Dianthus Therapeutics (NASDAQ:DNTH), sold over $2.2 million worth of company common stock and acquired $357,599 through option exercises. These transactions occurred on August 7 and 10, 2026, under a pre-established trading plan, as the stock trades near its 52-week …
An insider at Dianthus Therapeutics (DNTH) has sold shares valued at $844,822, as disclosed in a recent SEC filing. This transaction, reported on August 11, 2026, follows another recent insider sale of $2,208,833. Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe …
Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the company's stock for approximately $1.78 million, reducing his stake by over 80%. This transaction occurred as the company's shares fell 3.0% to $108.49, following a quarterly earnings report that missed EPS estimates but …
Dianthus Therapeutics Director Simon Read sold 2,777 shares of the company's stock for over $304,000, reducing his stake by 50%. This transaction occurred as DNTH shares experienced a 3.0% decline following a quarterly earnings report that missed EPS estimates, despite revenue exceeding expectations. Analysts …
Adam M. Veness, an insider at Dianthus Therapeutics, Inc. (DNTH), has filed a Rule 144 notice to sell 16,167 common shares valued at $1,760,909.64. The transaction, scheduled for August 10, 2026, involves an exercise of stock options for cash on the same date and …
The California State Teachers Retirement System significantly increased its stake in Dianthus Therapeutics (DNTH) by 155.5% in the first quarter, now owning 40,584 shares valued at $3.4 million. Despite this institutional confidence and generally positive analyst ratings, the company faces risks including ongoing losses, …
Dianthus Therapeutics Inc is projected to report a loss of 86 cents per share. This information comes from an earnings preview provided by Reuters, accessible through TradingView News. The full article and more content from various news sources are available with an unlimited access …
Marino Garcia, CEO of Dianthus Therapeutics (NASDAQ:DNTH), sold 166,000 shares totaling approximately $17.95 million on August 7, 2026, following the exercise of stock options. The sale occurred near the stock's 52-week high after a significant 481% return, aligning with an analyst valuation suggesting the …
This article reports on Dianthus Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of 40,000 shares of common stock with an aggregate market value of $4,396,800.00, resulting from the exercise of stock options. The filing has …
Dianthus Therapeutics CEO Marino Garcia sold 166,000 shares of the company's stock for approximately $17.95 million, reducing his direct ownership by 71.77%. The sale occurred on August 7th, with shares trading at $108.11 on average. Despite missing recent earnings estimates, the company's stock is …
Dianthus Therapeutics CEO and President Marino Garcia exercised options for 166,000 shares at $8.44 each, increasing his direct holdings. Subsequently, he sold these 166,000 shares at prices ranging from $107.49 to $110.76, reducing his direct common stock holdings to 65,292 shares. The total value …
T. Rowe Price Investment Management, Inc. has reported a 7.1% stake in Dianthus Therapeutics Inc.'s common stock, totaling 3,888,456 shares. The investment firm holds sole voting power over 3,884,903 shares and sole dispositive power over all 3,888,456 shares. Despite this, T. Rowe Price explicitly …
Raymond James has increased its target price for Dianthus Therapeutics Inc. to $131 from $125. The article, sourced from Reuters, indicates this change in financial outlook for the company. The content primarily highlights this price target adjustment.
The average 12-month price target for Dianthus Therapeutics, Inc. (DNTH) stock has increased from $129.77 to $133.79, according to 14 analysts. This updated target suggests a potential upside of approximately 21% from its August 4th closing price. The consensus rating for DNTH remains a …
HC Wainwright has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $130 to $158, maintaining a "buy" rating and suggesting a 40% upside. Despite a positive consensus from analysts, Weiss Ratings reiterated a "sell" rating. The company reported a quarterly loss of $0.90 …
H.C. Wainwright has increased its target price for Dianthus Therapeutics, Inc. (DNTH.O) to $158 from the previous $130. This update was reported by Reuters on August 6, 2026. The article highlights this specific financial analyst action regarding the biotechnology company.
Wedbush has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) to $122.00 from $105.00, reiterating an "outperform" rating, which suggests a potential 10% upside. This comes despite the company missing quarterly EPS estimates with a loss of $0.90 per share, though revenue exceeded expectations. …
Dianthus Therapeutics (NASDAQ:DNTH) reported a quarterly loss of $0.90 per share, missing analyst expectations by $0.05, despite revenue of $0.76 million exceeding the consensus estimate of $0.30 million. Following the announcement, shares rose 4.6% to $110.92. Analysts maintain a "Moderate Buy" rating with an …
Dianthus Therapeutics, Inc. (DNTH) announced Q2 license revenue of $761K. The company is a clinical-stage biotechnology firm focused on therapies for severe autoimmune diseases, with its lead candidate, claseprubart, in Phase 3 trials. Analysts currently have a "BUY" consensus rating for DNTH with an …
Dianthus Therapeutics reported a widened Q2 net loss of $50.2 million due to increased operating expenses, primarily driven by higher R&D costs for its clinical programs. Despite the loss, the company ended Q2 with $1.2 billion in cash, expected to fund operations into 2030, …
Dianthus Therapeutics has announced DNTH312, a new first-in-class, next-generation bifunctional fusion protein aimed at treating severe autoimmune diseases. This investigational drug combines claseprubart and TACI, targeting both active C1s and BAFF/APRIL pathways to provide comprehensive inhibition of B cell activity and Classical Pathway inflammation. …
Dianthus Therapeutics has granted 87,000 stock options to six new non-executive employees. These options, with a 10-year term and an exercise price of $106.02 per share, vest over four years and were approved under Nasdaq rules to incentivize new hires. Dianthus is a clinical-stage …
Dianthus Therapeutics, Inc. has announced the issuance of inducement grants to six newly-hired, non-executive employees on August 3, 2026. These grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock with …
Sei Investments Co. significantly increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 566.3%, acquiring an additional 78,388 shares in the first quarter, bringing its total to 92,229 shares valued at $7.74 million. Other institutional investors also adjusted their holdings, with several analysts reiterating …
DV Trading LLC recently acquired 26,551 shares of Dianthus Therapeutics (NASDAQ:DNTH) valued at approximately $2.23 million. Despite a recent 5.1% drop in stock price, Dianthus Therapeutics reported better-than-expected quarterly losses, and analysts maintain a "Moderate Buy" rating with a target price of $117.82. However, …
Dianthus Therapeutics (Nasdaq:DNTH) is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. The company's stock has seen significant growth (399.2% in 1 year) but faces risks including past shareholder dilution and current unprofitability. Recent developments include the initiation of a Phase 3 …
Dianthus Therapeutics' stock has reached a new 52-week high of $108.37, driven by strong performance and investor confidence, with a 1-year change of 419.16%. The company is financially sound with more cash than debt and has initiated a Phase 3 trial for its lead …
Search by ticker symbol or company name and select a result to open its chart.